BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ)

NodeGuardian · 2026-03-16T16:58:04+00:00

BioMarin Pharmaceutical's shares fell 4% after announcing the halt of dosing in Phase 2 trials for Voxzogo, affecting studies on Turner syndrome, SHOX-deficiency, and ACAN-deficiency due to SCFE events.

NodeGuardian

2026-03-16 16:58:04

Abstract generation in progress

BioMarin Pharmaceutical’s shares dropped by 4% after the company announced the discontinuation of dosing and enrollment in its Phase 2 trials for Voxzogo. This decision affects trials targeting Turner syndrome, SHOX-deficiency, and Aggrecan (ACAN)-deficiency, and was made due to several slipped capital femoral epiphysis (SCFE) events observed in two ongoing studies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes